海思科：创新药HSK39297片新适应症临床试验获批

Core Viewpoint - The company, Haishi Ke (002653), has received approval from the National Medical Products Administration for its new drug HSK39297, aimed at treating age-related macular degeneration (AMD) [1] Group 1: Drug Development - HSK39297 is a novel drug developed independently by the company, possessing its own intellectual property rights [1] - Preclinical research indicates that the drug has a clear target, confirmed efficacy, and good safety profile, making it a promising small molecule drug [1] - The drug is expected to have a high benefit/risk ratio in clinical applications, indicating its potential for successful treatment outcomes [1] Group 2: Market Potential - The approval of HSK39297 addresses the current shortage of effective clinical treatments for AMD, highlighting its broad clinical application prospects [1] - The drug is anticipated to become an effective treatment option for AMD, which is a significant unmet medical need in the market [1]